Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ResMed Inc. Common Stock (NY:RMD)

252.26 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ResMed Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
ResMed, Insulet, Lantheus, Inspire Medical Systems, and Evolent Health Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading. 
Via StockStory
Topics Economy
Top S&P500 movers in Wednesday's session
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday. 
Via Chartmill
These S&P500 stocks are gapping in today's session
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Wednesday. Discover the gap up and gap down stocks in the S&P500 index. 
Via Chartmill
Meta, Microsoft Power Wall Street To New Records Despite Inflation Jump: What's Moving Markets Thursday?
A post-earnings surge in Meta Platforms Inc. (NASDAQ:META) and Microsoft Corp. 
Via Benzinga
Topics Economy
Earnings Scheduled For July 31, 2025
 
Via Benzinga
Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority
New global clinical insights initiative debuts at World Sleep Congress 2025 to help drive innovation in sleep health care 
From Resmed, Inc.
Via GlobeNewswire
ResMed Inc. (NYSE:RMD): A Top Dividend Stock for Sustainable Income and Growth
ResMed (RMD) is a top dividend stock with a low payout ratio, strong financial health, and consistent growth, ensuring sustainable income for investors. 
Via Chartmill
2 S&P 500 Stocks to Target This Week and 1 That Underwhelm
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,... 
Via StockStory
Topics Stocks
3 Reasons Investors Watch ResMed (RMD)
ResMed has had an impressive run over the past six months as its shares have beaten the S&P 500 by 11.9%. The stock now trades at $281.96, marking a 20.7% gain. This was partly due to its solid... 
Via StockStory
Topics Government Stocks
These S&P500 stocks are gapping in today's session
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Wednesday. Discover the gap up and gap down stocks in the S&P500 index. 
Via Chartmill
Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds
Published in The Lancet Respiratory Medicine, research reveals sharp rise in OSA, especially among women, highlighting the need for earlier diagnosis, preventative strategies, and personalized care 
From Resmed, Inc.
Via GlobeNewswire
1 Mooning Stock to Target This Week and 2 We Brush Off
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions. 
Via StockStory
Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awards and 10,000 Patents and Designs
Milestones underscore Resmed’s leadership and commitment to delivering life-changing health technology that people love 
From Resmed, Inc.
Via GlobeNewswire
Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio
From Resmed, Inc.
Via GlobeNewswire
RMD Q2 Deep Dive: Margin Expansion and Product Innovation Drive Outperformance
Medical device company ResMed (NYSE:RMD) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.2% year on year to $1.35 billion. Its non-GAAP profit of $2.55 per share... 
Via StockStory
Topics Artificial Intelligence Economy
ResMed Inc (NYSE:RMD): A Strong Dividend Stock with Growth Potential and Financial Stability
ResMed (RMD) offers a strong dividend with steady growth, backed by solid profitability and financial health, making it ideal for long-term income investors. 
Via Chartmill
Discover the top S&P500 movers in Tuesday's pre-market session.
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. 
Via Chartmill
ResMed RMD Q4 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Stay informed with the top movers within the S&P500 index on Monday.
Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
The Analyst Verdict: ResMed In The Eyes Of 8 Experts
 
Via Benzinga
ResMed Analysts Increase Their Forecasts After Strong Q2 Earnings
 
Via Benzinga
ResMed (RMD) Stock Is Up, What You Need To Know
Shares of medical device company ResMed (NYSE:RMD) jumped 3.1% in the afternoon session after the company reported strong fourth-quarter financial results that surpassed analyst estimates. 
Via StockStory
Apple To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
ResMed (NYSE:RMD) Surprises With Q2 Sales
Medical device company ResMed (NYSE:RMD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 10.2% year on year to $1.35 billion. Its non-GAAP profit of $2.55 per share was 3% above... 
Via StockStory
Resmed Inc. (NYSE:RMD) Beats Q4 2025 Revenue and EPS Estimates Despite Muted Market Reaction
Resmed Inc. (NYSE:RMD) beats Q4 2025 revenue and EPS estimates, reporting $1.35B and $2.55, respectively. Stock dips slightly amid muted market reaction despite strong growth and dividend hike. 
Via Chartmill
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025
From Resmed, Inc.
Via GlobeNewswire
ResMed (RMD) To Report Earnings Tomorrow: Here Is What To Expect
Medical device company ResMed (NYSE:RMD) will be reporting earnings this Thursday afternoon. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Analyst Expectations For ResMed's Future
 
Via Benzinga
2 Reasons to Watch RMD and 1 to Stay Cautious
ResMed trades at $254.11 per share and has stayed right on track with the overall market, gaining 8.9% over the last six months. At the same time, the S&P 500 has returned 5.4%. 
Via StockStory
Topics Government Stocks
Motley Fool Co-Founder David Gardner Reviews Stock Picks
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.